Development candidate chosen for leukaemia program

Development candidate chosen for leukaemia program

Redx, the drug development company, is pleased to announce that it has identified a drug development candidate for its reversible Bruton’s tyrosine kinase (“BTK”) inhibitor program. The compound, named RXC005, has the potential to treat the majority of patients suffering from chronic lymphocytic leukaemia (“CLL”), including those who become resistant to the increasingly used treatment ibrutinib.

RXC005 is equally potent against the most common type of BTK protein implicated in CLL and the mutant BTK protein, which is currently estimated to be responsible for around 60% of the observed ibrutinib resistance. Redx’s BTK inhibitor could also offer a reduced side-effect profile compared to ibrutinib.

The Company will now progress studies to prepare the RXC005 program for first-in-human clinical trials. These trials are currently expected to commence in early 2018.

Dr Neil Murray, CEO of Redx, said:

“We’re delighted to announce another cancer drug candidate from our innovative development pipeline. The nomination of RXC005, a novel reversible BTK inhibitor, comes within a month of confirming the planned start of clinical trials for our most advanced program, the Porcupine inhibitor, in some hard-to-treat cancers.

“RXC005 has the potential to become a potent therapy for chronic lymphocytic leukaemia patients, including those resistant to ibrutinib treatment. We plan to initiate first-in-human studies for RXC005 early 2018.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.